Seeking Alpha

TapeBeat's  Instablog

TapeBeat
Send Message
Philip Runfeld single-handedly founded and operated companies grossing nearly a million dollars a year, prior to becoming a sought after business consultant to some of the country’s leading Fortune 500 companies, such as Disney, Marriott International and DuPont Chemical. Certified by the U.S.... More
My company:
TapeBeat.Com
  • Keep your eyes wide open 8 comments
    Feb 18, 2010 1:37 AM | about stocks: NBS, EPRS, CEMI
    by Philip Runfeldt and Staff Writers

    For the past couple of days, the market was doing relatively well. Consequently, we expect the market to retract as the bears are fighting the bulls. 

    Additionally, the stocks that we have are eyes on are: NBS, CRXX, CEMI, HDVY. All of those have a nice science behind them and we believe that nice gains can be made with them. So keep your eyes opened.


    Stocks: NBS, EPRS, CEMI
Back To TapeBeat's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (8)
Track new comments
  • larry luv
    , contributor
    Comments (130) | Send Message
     
    My Eyes are Wide open for Chembio (CEMI.OB)
    Earnings release Mar.5 will show expected revenue increases and a few Company Milestones are expected next few Quarters.
    pps in .29 .30 range for a very long time.
    Nice buy-in price...
    Bling Bling''
    23 Feb 2010, 06:41 PM Reply Like
  • Chemistfrog
    , contributor
    Comments (285) | Send Message
     
    I'm in CRXX and absolutely could not sell this passed Friday when the selling pressure was on. Monday, March 1 is PDUFA decision day, and I'm expecting to see approval although the subsequent PPS is way up in the air. This is simply Palladone's active ingredient in a different matrix that does not dump all its drug that is supposed to be slow-release when alcohol is present. CRXX and COV learned from Perdue Pharma's mistake and formulated the drug in such a way that its extended-release profile isn't compromised when exposed to ethanol in alcoholic drinks. I think there is better than a 70% chance of approval on Monday and 100% chance by August so it's a win-win!
    28 Feb 2010, 07:40 AM Reply Like
  • lyndia
    , contributor
    Comments (3) | Send Message
     
    All I can say is 'point proven' (see my commentary on CRXX shake out) I am appalled that this happening once again to a company with strong potential ,Chembio, CEMI. I have also done my share of dd, as usual and just have to sit by and watch these robots play a virtual game in a real world. Good luck to both companies. Lyndia
    1 Mar 2010, 12:58 PM Reply Like
  • larry luv
    , contributor
    Comments (130) | Send Message
     
    Chembio got bad News from Europe
    They Did NOT get CE Mark for the Clearview HIV tests
    More Data/Information was needed by Authorities but Shockingly' >Chembio announced they are giving up pursuit' in Europe and will not attempt to get Marketing there for this product..
    Expectations were increases in Company revenues of 30-50% with European sales' -It aint Happening'
    This was terrible News from Chembio...
    9 Mar 2010, 10:35 AM Reply Like
  • mvana2
    , contributor
    Comment (1) | Send Message
     
    Just started following POC Diagnostics space. Interesting…particularly HIV test products. Looks like a 2-horse race, with huge markets in Africa and South America. Caught Chembio’s earnings announcement couple weeks ago. Tracking well, year to year. Think I'll get in and play around a little bit.
    16 Mar 2010, 11:27 AM Reply Like
  • yseclov
    , contributor
    Comments (18) | Send Message
     
    I like the approval that Cemi HVI test can now be funded by PEPFAR
    This could be big..... very big!
    3 Apr 2010, 06:56 AM Reply Like
  • TapeBeat
    , contributor
    Comments (2) | Send Message
     
    Author’s reply » Yes, hopefully it will hit big but its a low profile for now.
    4 Apr 2010, 01:16 AM Reply Like
  • yseclov
    , contributor
    Comments (18) | Send Message
     
    Stay with this puppy. It digested the gains well and stochastics are back in a reasonable range. The have many new products on the back burner and DPP works of Biorad would not have paid for the license and Brazil would not be using their products. Just need FDA approval for some DPP products. Look at OSUR $5.25 a share and CEMI has a better product.
    4 Dec 2010, 11:08 PM Reply Like
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.